De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

INOVIQ Beheer

Beheer criteriumcontroles 2/4

De CEO INOVIQ's is Leearne Hinch, benoemd in Nov2016, heeft een ambtstermijn van 7.92 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 609.31K, bestaande uit 68% salaris en 32% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde A$ 132.58K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 5.3 jaar.

Belangrijke informatie

Leearne Hinch

Algemeen directeur

AU$609.3k

Totale compensatie

Percentage CEO-salaris	68.0%
Dienstverband CEO	7.9yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.1yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

Nov 22

Recent updates

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

Apr 22

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

Mar 01

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

Nov 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Mar 02

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

Dec 28

Analyse CEO-vergoeding

Hoe is Leearne Hinch's beloning veranderd ten opzichte van INOVIQ's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$609k	AU$414k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$7m
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$8m
Jun 30 2023	AU$558k	AU$396k	-AU$9m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$21m
Sep 30 2022	n/a	n/a	-AU$20m
Jun 30 2022	AU$485k	AU$376k	-AU$18m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	n/a	n/a	-AU$11m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$867k	AU$330k	-AU$11m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$712k	AU$330k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$2m
Sep 30 2019	n/a	n/a	-AU$2m
Jun 30 2019	AU$442k	AU$361k	-AU$2m
Mar 31 2019	n/a	n/a	-AU$2m
Dec 31 2018	n/a	n/a	-AU$2m
Sep 30 2018	n/a	n/a	-AU$2m
Jun 30 2018	AU$403k	AU$359k	-AU$2m

Compensatie versus markt: De totale vergoeding ($USD 420.50K ) Leearne } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 312.49K ).

Compensatie versus inkomsten: De vergoeding van Leearne is gestegen terwijl het bedrijf verliesgevend is.

CEO

Leearne Hinch

7.9yrs

Tenure

AU$609,311

Compensatie

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of INOVIQ Ltd (formerly known as BARD1 Life Sciences Limited) since November 7, 2016. Dr. Hinch is a biotech...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Leearne Hinch	Chief Executive Officer	7.9yrs	AU$609.31k	0.25% A$ 130.3k
Mark Edwards	CFO & Company Secretary	1.9yrs	AU$322.87k	0.036% A$ 19.0k
Gregory Rice	Chief Scientific Officer	3.1yrs	AU$350.25k	0.054% A$ 28.5k

3.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van IIQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Powell	Independent Non-Executive Director	5.3yrs	AU$62.90k	0.48% A$ 253.9k
David Williams	Non-Executive Chairman	less than a year	AU$729.81k	4.6% A$ 2.4m
Geoffrey Cumming	Independent Non-Executive Director	4.3yrs	AU$74.93k	0.21% A$ 112.8k
Robert Johnston	Independent Non-Executive Director	5.3yrs	AU$62.90k	0.54% A$ 287.0k
Samuel Janes	Member of Advisory Board	7.3yrs	geen gegevens	geen gegevens
Mary Harney	Non-Executive Director	no data	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van IIQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

INOVIQ Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

INOVIQ Ltd, Annual General Meeting, Nov 28, 2023

Insufficient new directors

INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director

INOVIQ Limited Announces Company Secretary Changes

INOVIQ Ltd, Annual General Meeting, Nov 28, 2022

Recent updates

Consensus EPS estimates fall by 17%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

INOVIQ Ltd to Report Fiscal Year 2024 Results on Aug 21, 2024

INOVIQ Ltd has completed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Shareholder dilution

INOVIQ Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Share price stability

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

INOVIQ Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings released: AU$0.097 loss per share (vs AU$0.20 loss in FY 2022)

Insufficient new directors

Inoviq Limited Announces Clinical Validation Study for Subb2m/Ca15-3 Breast Cancer Test

New minor risk - Share price stability

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

First half 2023 earnings released: AU$6.70 loss per share (vs AU$0.031 loss in 1H 2022)

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

INOVIQ Limited Announces Positive Results for SubB2M Breast Cancer Test

INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director

INOVIQ Limited Announces Company Secretary Changes

INOVIQ Ltd, Annual General Meeting, Nov 28, 2022

INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: AU$0.072 loss per share (vs AU$0.14 loss in FY 2021)

High number of new directors

INOVIQ Limited Announces Positive SubB2M IHC Results for Melanoma

We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

High number of new and inexperienced directors

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

Inoviq Limited Announces Update on Legal Proceedings and Bard1 Autoantibody Program

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate

Full year 2021 earnings released: AU$0.14 loss per share (vs AU$0.072 loss in FY 2020)

Chief Scientific Officer Peter French has left the company

Chief Scientific Officer Peter French has left the company

BARD1 Life Sciences Limited Announces That Previously Reported Study Results for A Potential Bard1 Autoantibody Test for Early Detection of Ovarian Cancer in the International Peer-Reviewed Journal Genes

BARD1 Life Sciences Limited Announces SubB2M Breast Cancer Test Manuscript Submitted

Bard1 Life Sciences Limited Announces the Results of A Preliminary Study Which Demonstrates the Feasibility of Using Subb2m in an Ihc Application for Breast Cancer Tissue

BARD1 Life Sciences Limited Launches Its RUO EXO-NET Product

BARD1 Life Sciences Limited Presents BARD1 EXO-NET Exosome Data at ISEV2021 Conference

BARD1 Life Sciences Limited Announces Positive Results from the BARD1 autoantibody assay

BARD1 Life Sciences Limited Announces Positive Results Evaluation of EXO-NET in Pancreatic Cancer

BARD1 Life Sciences Limited Receives the Initial Purchase Order for AUD 80,000 from Mirax for hTERT

Bard1 Life Sciences Limited Gains Class II In-Vitro Diagnostic Medical Device Registration from South Korea's Ministry of Food and Drug Safety for the hTERT Test

Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Insider recently sold AU$8.2m worth of stock

BARD1 Life Sciences Limited Releases SUBB2M BREAST CANCER TEST DATA

Bard1 Life Sciences Limited Announces Outstanding SubB2M Ovarian Cancer Test Data

New 90-day low: AU$0.57

Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited

New 90-day low: AU$0.61

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

New 90-day low: AU$0.66

New 90-day low: AU$0.66

BARD1 Life Sciences Limited Announces Resignation of Helen Fisher as Non-executive Director

BARD1 Life Sciences Limited Gains New High-Volume Customer for Its hTERT test

BARD1 Life Sciences Limited Announces the Successful Evaluation of the BARD1 kit

BARD1 Life Sciences Limited Auditor Raises 'Going Concern' Doubt

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur